COVID-19 outcomes in persons with multiple sclerosis treated with rituximab
Author:
Publisher
Elsevier BV
Subject
Neurology (clinical),Neurology,General Medicine
Reference29 articles.
1. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study;Avouac;Lancet Rheumatol.,2021
2. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma;Berinstein;Ann. Oncol.,1998
3. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response;Bonelli;Ann. Rheum. Dis.,2021
4. Reactivation of SARS-CoV-2 after rituximab in a patient with multiple sclerosis;Bose;Mult. Scler. Relat. Disord.,2021
5. Rituximab for the treatment of multiple sclerosis: a review;Chisari;J. Neurol.,2021
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Anti-RBD Antibody Levels and IFN-γ-Specific T Cell Response Are Associated with a More Rapid Swab Reversion in Patients with Multiple Sclerosis after the Booster Dose of COVID-19 Vaccination;Vaccines;2024-08-19
2. The Influence of SARS-CoV-2 Infection on the Development of Selected Neurological Diseases;International Journal of Molecular Sciences;2024-08-09
3. Low-dose rituximab regimen does not increase severe COVID-19 risk in patients with neuroimmune diseases during the pandemic: a cross-sectional study;2024-07-29
4. COVID-19 Infection in Multiple Sclerosis Patients Treated with Rituximab Compared to Natalizumab and Healthy Controls: A Real-World Multicenter Study;Annals of Indian Academy of Neurology;2024-05
5. Rituximab treatment for refractory and moderate-to-severe pemphigus patients in the pandemic era: A single-center retrospective study;Dermatologica Sinica;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3